Shukra Pharmaceuticals Ltd.

As of June 30, 2026, Shukra Pharmaceuticals Ltd. has 439.61M shares outstanding.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 4.59M in revenue per employee across its workforce of 163.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Shukra Pharmaceuticals Ltd. recorded 115.98M in income tax expense. That works out to an effective tax rate of 25.44, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 455.83M, leaving 339.85M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Over the twelve months ended June 30, 2026, Shukra Pharmaceuticals Ltd. generated 748.59M in revenue and converted that into 339.85M in net income, yielding earnings per share of 0.77. EBITDA reached 465.61M, while operating income came in at 428.23M.

Over the twelve months ended June 30, 2026, Shukra Pharmaceuticals Ltd. posted a gross margin of 81.91, reflecting its pricing power and cost economics. The operating margin of 57.20 and net profit margin of 45.40 provide insight into operational efficiency.

Shukra Pharmaceuticals Ltd.'s most recent stock split took place on March 21, 2025 with a 1:10 split ratio.